Sugi Predict

Sugi Predict / Compounds / SCHEMBL3044171

SCHEMBL3044171

SCHEMBL3044171

COc1cc2c(cc1OC)C(C)(C)/C(=C\c1ccccc1)C2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 4/20 0.42
▸ MAOB P27338 4/20 0.42
▸ APP P05067 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ RET P07949 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39
▸ TUBA4A P68366 1/20 0.39
▸ TUBB4B P68371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365202 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL301682 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL303097 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL15040995 0.94 ACHE (0.39) ACHEMAOBAPPKMT2AMEN1
SCHEMBL15040993 0.81 MAOB (0.38) MAOBKMT2AMEN1ALDH1A1MAPT
SCHEMBL15040971 0.81 MAOB (0.38) MAOBKMT2AMEN1ALDH1A1MAPT
SCHEMBL21098267 0.79 CA1 (0.41) ACHEMAOBAPPKMT2AMEN1
SCHEMBL12977425 0.78 MAPT (0.53) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL12977423 0.78 MAPT (0.53) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL16746500 0.77 HPGD (0.44) MAOBKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2931382-B1 ACTIVE SUBSTANCE COMBINATION FOR SKIN LIGHTENING I HENKEL AG & CO KGAA (DE) 2018-06-27 — — EP claimed
US-20220031628-A1 NANOPARTICLES FOR PREPARING REGULATORY B CELLS UNIVERSITÉ PARIS CITÉ (FR) 2022-02-03 — — US disclosed
US-20210220481-A1 BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES UNIVERSITÉ PARIS CITÉ (FR) 2021-07-22 — — US disclosed
US-10857089-B2 Cosmetic compositions comprising purple coneflower pressed juice SYMRISE AG (DE) 2020-12-08 — — US disclosed
EP-3097905-B1 COSMETIC COMPOSITIONS SYMRISE AG (DE) 2020-11-04 — — EP disclosed
US-10780043-B2 Cosmetic compositions comprising ginger root extracts SYMRISE AG (DE) 2020-09-22 — — US disclosed
US-10780042-B2 Cosmetic compositions SYMRISE AG (DE) 2020-09-22 — — US disclosed
WO-2020109352-A1 NANOPARTICLES FOR PREPARING REGULATORY B CELLS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2020-06-04 — — WO disclosed
US-10357447-B2 Cosmetic compositions comprising sclareolide SYMRISE AG (DE) 2019-07-23 — — US disclosed
EP-2931382-B1 ACTIVE SUBSTANCE COMBINATION FOR SKIN LIGHTENING I HENKEL AG & CO KGAA (DE) 2018-06-27 — — EP disclosed
WO-2013034685-A1 MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2013-03-14 — — WO disclosed
US-7855310-B2 AH receptor antagonists SYMRISE GMBH & CO. KG (DE) 2010-12-21 — — US disclosed
US-7855310-B2 AH receptor antagonists SYMRISE GMBH & CO. KG (DE) 2010-12-21 — — US disclosed
EP-2238967-A2 Skin treatment fighting skin aging II Henkel AG & Co. KGaA (DE) 2010-10-13 — — EP disclosed
EP-2238968-A2 Skin treatment fighting skin aging Henkel AG & Co. KGaA (DE) 2010-10-13 — — EP disclosed
EP-2238967-A2 Skin treatment fighting skin aging II Henkel AG & Co. KGaA (DE) 2010-10-13 — — EP disclosed
EP-2238968-A2 Skin treatment fighting skin aging Henkel AG & Co. KGaA (DE) 2010-10-13 — — EP disclosed
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation SYMRISE GMBH & CO., KG (DE) 2009-08-20 — — US disclosed
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation SYMRISE GMBH & CO., KG (DE) 2009-08-20 — — US disclosed
WO-2007128723-A1 AH RECEPTOR ANTAGONISTS SYMRISE GMBH & CO. KG (DE) 2007-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10857089-B2 Cosmetic compositions comprising purple coneflower pressed juice DNER, CDYL2, NOTCH2 ACHE 3762/4885MAOB 4369/4885APP 3747/4885
US-20210220481-A1 BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES IAPP, AHR, ARNT ACHE 4276/4885MAOB 4386/4885APP 468/4885
US-10780043-B2 Cosmetic compositions comprising ginger root extracts DNER, CDYL2, NOTCH2 ACHE 2899/4885MAOB 4029/4885APP 3853/4885
US-10357447-B2 Cosmetic compositions comprising sclareolide DNER, CDYL2, CDYL ACHE 3440/4885MAOB 4498/4885APP 4318/4885
US-20220031628-A1 NANOPARTICLES FOR PREPARING REGULATORY B CELLS IAPP, IL2, CCR10 ACHE 3876/4885MAOB 3767/4885APP 933/4885
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation AHR, ARNT, AIPL1 ACHE 4669/4885MAOB 1847/4885APP 2030/4885
US-10780042-B2 Cosmetic compositions DNER, CDYL2, CDYL ACHE 3702/4885MAOB 4378/4885APP 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.